| May 4, 2008: Treatment of hypertension in the very old reduces all-cause mortality HYVET published: This randomized, placebo-controlled trial demonstrated that treatment of stage II hypertension in patients over 80 years of age reduced the incidence of stroke and all cause mortality. |
| April 23, 2008: CoStar Drug Eluting Stent is not Non-inferior to TAXUS Drug Eluting Stents The CoStar (Cobalt Chromium Stent With Antiproliferative for Restenosis) II trial demonstrates that the CoStar drug eluting stent is not non-inferior to Taxus drug eluting stent based on the angiographic and clinical outcome analyses at 9 months. |
| April 1, 2008:
High dose tirofiban and clopidogrel are safe and effective in
the ON-TIME-2 trial The ON-TIME-2 investigators demonstrated
that the early administration of high dose tirofiban together
with 600mg of clopidogrel is safe and effective among patients
with acute ST segment elevation myocardial infarction undergoing
PCI. Download the slides |
| April 1, 2008:
Implantation of skeletal myoblasts into scarred myocardium
improves symptoms but not heart function The SEISMIC study
demonstrates that administration of skeletal myoblast improves
symptoms in patients with heart failure with no effect on left
ventricular function and dimensions. Download the slides |
| April 1, 2008:
Reloading With Clopidogrel Improves Clinical Outcomes in
Patients with Acute Coronary Syndromes: ARMYDA-RELOAD
Results from the ARMYDA-RELOAD trial demonstrate improved
clinical outcomes when patients with acute coronary syndromes
already on clopidogrel are administered an additional 600mg
prior to PCI but not for patients with stable angina. Download the slides |
| April 1, 2008:
MEND-CABG II trial does not suggest improved outcomes with the
novel drug MC1 in patients undergoing high risk coronary artery
bypass surgery A novel drug MC-1 used during coronary artery
bypass surgery (CABG) does not result in improved cardiovascular
outcomes. Download the slides |
| April 1, 2008:
ExoSeal® Vascular Closure Device is safe and effective
Results from the ECLIPSE trial demonstrate the superiority of
the ExoSeal® Vascular Closure Device compared to manual
compression in reducing both the time to hemostasis and the time
to ambulation following intervention. Download the slides |
| April 1, 2008:
The ASTRAL Trial Demonstrates Angioplasty and Stenting Offer No
Benefit Over Medical Therapy in Patients with Renal Arterial
Stenoses Results from the ASTRAL trial demonstrate that
there were no improvements in kidney function, blood pressure
control, or rates of major cardiovascular illness in patients
who receives catheter-based interventions for renal artery
stenosis compared with those treated with medical therapy alone.
Download the slides |
| April 1, 2008:
Standard Physician Care for Heart Failure is Just as Effective
as and Less Expensive Than a Home Monitoring System The
Heart Failure Home Care (HFHC) trial demonstrates that HF
patients receiving standard follow-up care from a physician have
just as good of a clinical result and a better economic outcome
than those using a home-monitoring interactive system. Download the slides |
| April 1, 2008:
Similar nephrotoxic effects with iodixanol and iomeprol in the
CONTRAST trial The CONTRAST trial demonstrates that the
nephrotoxic effects are similar with the iso-osmolar contrast
media (iodixanol 320) versus low-osmolar contrast media
(iomeprol 350) in patients with impaired renal function
undergoing percutaneous coronary intervention. Download the slides |
| April 1, 2008:
Atrial tachyarrhythmia burden ≥5.5h in a day doubles the risk
for thromboembolism in the TRENDS study Device-detected
atrial fibrillation (AF), a commonly diagnosed cardiac
arrhythmia, may increase the risk of stroke, even in brief AF
episodes, according to the TRENDS study presented today at ACC
08. Download the slides |
| April 1, 2008:
The EVEREST trial suggests MitraClip® for mitral regurgitation
is effective Percutaneous mitral valve repair with the
Mitraclip® device for functional mitral regurgitation is
effective with low major adverse events and significant reverse
remodeling at one year in the initial EVEREST cohort. Download the slides |
| April 1, 2008:
Rimonabant does not reduce atherosclerosis progression in
STRADIVARIUS Treatment of patients with abdominal obesity
with rimonabant reduces body weight and waist circumference but
not atherosclerosis progression. Download the slides |
| April 1, 2008:
Automated External Defibrillators offer no benefit in cardiac
arrests that occur at home in the HAT trial Results from the
HAT trial demonstrate that survival rates did not improve among
patients with access to a home AED compared with patients with
only an EMS call and a companion with CPR training. Download the slides |
| April 1, 2008:
Cardiac Resynchronization Therapy and Optimal Medical Therapy
May Reverse Left Ventricular Remodeling in the REVERSE trial
Cardiac resynchronization therapy (CRT) along with optimal
medical therapy (OMT), may reverse left ventricular remodeling
in patients with mild or no heart failure symptoms according to
the REVERSE study. Download the slides |
| April 1, 2008:
Insertable Loop Recorder Tracks Cardiac Arrhythmias Following
Acute Myocardial Infarction Results of the CARISMA trial
demonstrate that the insertable loop recorders (ILR) can
document cardiac arrhythmias following myocardial infarction.
Download the slides |
| March 31, 2008:
Pioglitazone Prevents Progression of Coronary Atherosclerosis in
Diabetic Patients With Coronary Artery Disease: Results of the
PERISCOPE Trial Results of the PERISCOPE trial reveal that
pioglitazone slows progression of plaque in type 2 diabetic
patients with coronary artery disease in comparison to
glimepiride. Download the slides |
Download the slides |
| March 31, 2008:
Treatment of hypertension with indapamide with or without
perindopril is beneficial in the elderly: Results from the HYVET
study Results of the HYpertension in the Very Elderly Trial
(HYVET) demonstrate a benefit in the antihypertensive treatment
of persons at least 80 years old with or without perindopril.
Download the slides |
| March 31, 2008: Cardiovascular risk increases with incremental doses of celecoxib Pooled data from a six-study analysis recommends the lowest dose possible of celecoxib for patients who derive benefit from the drug. |
| March 31, 2008:
Dual therapy better than monotherapy to treat hypertension in
the ACCOMPLISH trial The interim results from the ACCOMPLISH
trial demonstrated that patients with hypertension and at high
risk for CV complications experienced 20% fewer events with a
combination of an ace inhibitor and calcium channel blocker.
Download the slides |
| March 31, 2008:
The GENESIS Trial Demonstrates Disappointing Results With
Pimecrolimus Eluting Stents Results from the GENESIS trial
demonstrate that patients treated with CORIO™ (Pimecrolimus-eluting)
stents had worse outcomes compared with individuals treated with
SYMBIO™ (dual drug delivery of Pimecrolimus and Paclitaxel)
stents or the CoStar® (Paclitaxel-eluting) stents. Download the slides |
| March 31, 2008:
PEPCAD II ISR study suggests that drug eluting balloons are safe
and effective compared with drug eluting stents in treating
in-stent restenosis Paclitaxel-eluting balloons are
effective in reducing late lumen loss and 12 month major adverse
cardiac events (MACE) compared with drug eluting stents. Download the slides |
| March 31, 2008:
The Efficacy of XIENCE V Stent over Taxus Stent Decreases with
Time: Results from the SPIRIT II study The 2-year results of
the SPIRIT II study demonstrate no significant difference
between the outcomes obtained from implantation of the XIENCE V
everolimus-eluting stent or the TAXUS paclitaxel-eluting stent. |
| March 31, 2008:
Long Term Adherence to Clopidogrel and Late Adverse Cardiac
Events after Off-Label Use of Sirolimus-Eluting Stents: Results
of the MATRIX Registry Results from the MATRIX Registry, a
large community-based registry consisting of patients who were
treated with drug-eluting stents (DES), were presented today at
the SCAI-i2 summit Annual Scientific Sessions in Chicago by Dr.
George Dangas of Columbia University Medical Center. Download the slides |
| March 31, 2008:
Left main stenting is associated with similar rates of death, Q
wave myocardial infarction and stroke compared with CABG at
3-year follow-up A non-randomized study from Korea
demonstrate no significant difference in mortality rate or the
composite risk of death, Q-wave myocardial infarction or stroke
among patients undergoing stenting or surgery for unprotected
left main stem disease. Download the slides |
| March 31, 2008:
Excel biodegradable stents are safe and effective: Results from
the CREATE trial The 12 month clinical outcome of a
prospective multicenter registry of Excel™ biodegradable polymer
sirolimus eluting stents suggests that these stents are safe and
effective in the “real world” population. Download the slides |
| March 30, 2008:
Drug eluting stents are associated with reduced mortality in
patients with myocardial infarction at two years
Investigators from Boston demonstrated that the use of
drug-eluting stents is associated with reduced mortality at two
years compared with bare metal stents among patients with an
acute infarct. Download the slides |
| March 30, 2008:
High Dose Tirofiban is similar to Abciximab in reducing Major
Adverse Cardiac Events The Multistrategy study demonstrates
that high dose tirofiban is non-inferior to abciximab during PCI
for acute myocardial infarction and the use of sirolimus eluting
stents reduces major adverse cardiac events. Download the slides |
| March 30, 2008:
Abciximab in addition to a high loading dose of clopidogrel does
not improve outcomes in STEMI patients: Results from the BRAVE-3
Trial Investigators from Germany demonstrate that dual
therapy with high loading dose of clopidogrel (600 mg) and
intravenous abciximab does not improve outcomes in ST-elevation
myocardial infarction (STEMI) patients compared with clopidogrel
therapy alone. Download the slides |
| March 30, 2008:
Removal of debris from the coronary arteries does not improve
outcomes: Results from the A-F study Vascular protection in
high risk non-ST elevation acute coronary syndromes in the
Angioplasty Balloon-associated Coronary Debris and the EZ
Filter-wire (A-F) randomized, controlled trial did not improve
cardiovascular outcomes compared with conventional PCI. Download the slides |
| March 30, 2008:
Thrombus aspiration in patients with ST elevation myocardial
infarction improves mortality at 1 year in the TAPAS trial
Researchers from the Netherlands demonstrate that thrombus
aspiration during coronary angioplasty for acute myocardial
infarction improves one year mortality compared with
conventional PCI. Download the slides |
| March 30, 2008:
Early Transfer of AMI Patients for PCI improves cardiovascular
outcomes in the TRANSFER-AMI study The TRANSFER-AMI study
demonstrates improved cardiovascular outcomes with early PCI
following the administration of pharmacotherapy in patients
presenting to a non-PCI treatment center with acute myocardial
infarction (AMI). |
| March 29, 2008:
Bivalirudin is no better than heparin in patients pretreated
with clopidogrel undergoing PCI: Results from the ISAR-REACT-3
trial Investigators from Germany demonstrated that
bivalirudin is not superior to unfractionated heparin (UFH)
among stable patients pretreated with 600 mg of clopidogrel
undergoing PCI. Download the slides |
| March 29, 2008:
Culotte is better than crush for bifurcation lesions: Results
from the Nordic Stent Technique study Eight month
angiographic follow-up in patients randomized to crush or
culotte bifurcation stenting demonstrates that culotte technique
might be better with reduced side branch restenosis rates. Download the slides |
| March 29, 2008:
Percutaneous Coronary Interventions can be performed in centers
without on-site cardiac surgical back-up An analysis from
the National Cardiovascular Data Registry (NCDR) demonstrates
that PCI can be performed safely and successfully at medical
facilities without on-site cardiac surgical back-up. Download the slides |
| March 29, 2008:
TRITON-TIMI 38 stent analysis demonstrates that prasugrel is
better than clopidogrel in reducing the incidence of early and
late stent thrombosis The TRITON-TIMI 38 stent study
demonstrates that prasugrel is better than clopidogrel in
reducing the incidence of early and late stent thrombosis in
patients with acute coronary syndromes undergoing percutaneous
coronary intervention. Download the slides |
| March 29, 2008:
Platelet monitoring can improve outcomes following PCI among
clopidogrel resistant patients Investigators from France
demonstrate that platelet monitoring of clopidogrel response
using VASP phosphorylation index decreases the rate of major
adverse cardiovascular events in patients with clopidogrel
resistance. Download the slides |
| March 29, 2008:
High recurrence rate of stent thrombosis after the first event:
Results from the Dutch Stent Thrombosis Registry Results
from the Dutch Stent Thrombosis study demonstrate that the
implantation of an additional stent during emergency treatment
of the initial stent thrombosis is among the strongest
predictors of recurrent stent thrombosis. Download the slides |
|
This Week In Slides
Thursday, April 17, 2008: Long-Term Safety of DES in Off-Label Use: Results of the MATRIX Registry by Dr. George D. Dangas
Thursday, April 17, 2008: Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction: The HORIZONS AMI Trial by Dr. George D. Dangas
Thursday, April 17, 2008: Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty: The HORIZONS AMI Trial by Dr. Bernhard Witzenbichler
Thursday, April 17, 2008: Impact of gender on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The Horizons AMI Trial by Dr. L. Grinfield
Thursday, April 17, 2008: Impact of Baseline Renal Function on the Safety and Effectiveness of Bivalirudin in Patients with Acute MI Undergoing Primary Angioplasty: The HORIZONS AMI Trial by Dr. Roxana Mehran
Thursday, April 17, 2008: Impact of advanced age on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI Trial by Dr. Dariusz Dudek
Thursday, April 17, 2008: Major Adverse Events in STEMI Patients Treated with Primary Angioplasty Occur More Frequently at U.S. Compared with Non U.S. Sites: Analysis from the HORIZONS AMI Trial by Dr. Bruce R. Brodie
Thursday, April 17, 2008: Safety and effectiveness of bivalirudin compared to either abciximab or eptifibatide in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI Trial by Dr. Giulio Guagliumi
Monday, April 7, 2008: Trends in the Quality of Care of Patients with Acute Myocardial Infarction: The National Registry of Myocardial Infarction from 1990 to 2006 by Dr. Bimal R. Shah
Monday, April 7, 2008: Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency by Dr. Christoph Hammerstingl
Friday, April 4, 2008: Results of the Home Automated External Defibrillator Trial: HAT Trial by Dr. Gust H. Bardy
Thursday, April 3, 2008: Ongoing-Tirofiban In Myocardial Infarction Evaluation: ON-TIME-2 by Dr. Christian W. Hamm
Wednesday, April 2, 2008: REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction: Results of the REVERSE Trial by Dr. Cecilia Linde
Wednesday, April 2, 2008:
Long-term Cardiac Arrhythmias recorded by Insertable Loop Recorders in
Patients with depressed Left Ventricular Function after Acute Myocardial
Infarction: CARISMA by Dr. PE Bloch
Thomsen
Wednesday, April 2, 2008: Effect of Rimonabant on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease: STRADIVARIUS by Dr. Steven E. Nissen
Wednesday, April 2, 2008: Is There a Critical Value of Daily Atrial Tachyarrhythmia Burden from Device Diagnostics that Raises Stroke Risk? The TRENDS Study by Dr.Taya V. Glotzer
Wednesday, April 2, 2008: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk Coronary Artery Bypass Graft Surgery: Main Results of the MEND-CABG II Trial by Dr. John H. Alexander
Wednesday, April 2, 2008: The Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) using an Injection Catheter Trial: SEISMIC Trial by Dr. Patrick W. Serruys
Tuesday, April 1, 2008: Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial by Dr. Steven V. Manoukian
Tuesday, April 1, 2008:Major Bleeding Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial by Dr. Steven V. Manoukian
Tuesday, April 1, 2008: Transfusion is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results from the ACUITY Trial by Dr. Steven V. Manoukian
Tuesday, April 1, 2008: Percutaneous Mitral Repair with the MitraClip® Device for Functional Mitral Regurgitation: Results from the EVEREST Study by Dr. James Hermiller
Tuesday, April 1, 2008: Ensure’s Vascular Closure Device Speeds Hemostasis: ECLIPSE Trial by Dr. S. Chiu Wong
Tuesday, April 1, 2008: COntrast media and NephroToxicitr following coronary Revascularization by AngioplaSTy: CONTRAST by Dr. Rainer Wessely
Tuesday, April 1, 2008: Prospective, multicenter, randomized, double blind trial investigating influence on PCI outcome of additional 600 mg clopidogrel load in patients on chronic therapy: ARMYDA-Reload by Dr. Germano Di Sciascio
Tuesday, April 1, 2008: UK Multi-Centre Trial In Atherosclerotic Renovascular Disease: ASTRAL Trial by Dr. Philip A. Kalra
Monday, March 31, 2008: Comparison of Pioglitazone vs. Glimepiride on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes: PERISCOPE Trial by Dr. Steven E. Nissen
Monday, March 31, 2008: Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension: The ACCOMPLISH Trial
Monday, March 31, 2008: ONTARGET: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial by Salim Yusuf
Monday, March 31, 2008: The Astroid Trial: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden by Dr. Christie M. Ballantyne
Monday, March 31, 2008: The Hypertension in the Very Elderly Trial (HYVET) by Dr. Nigel S. Beckett
Monday, March 31, 2008: Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease: MAIN-COMPARE Study by Dr. Seung-Jung Park
Monday, March 31, 2008: Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease: PEPCAD II ISR Study by Dr. Martin Unverdorben
Monday, March 31, 2008: Long-Term Safety of DES in Off-Label Use: Results of the MATRIX Registry by Dr. George D. Dangas
Monday, March 31, 2008: A Randomized, Multi-center Study of the Pimecrolimus-Eluting and Paclitaxel-ElutinGCoronary Stent System in PatiENtswith De Novo LEsionSof the Native Coronary ArterIeS: The Genesis Trial by Dr. Stefan Verheye
Monday, March 31, 2008: CREATE Multi-Center Clinical Registry 9-month Angiographic and 12-month Clinical Results by Dr. Yaling Han
Sunday, March 30, 2008: Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study: TAPAS by Dr. Felix Zijlstra
Sunday, March 30, 2008: MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or bare metal stent in acute myocardial infarction studY: MULTISTRATEGY by Dr. Marco Valgimigli
Sunday, March 30, 2008: Drug-Eluting and Bare Metal Stenting for Acute Myocardial Infarction in Massachusetts by Dr. Lauri Mauri
Sunday, March 30, 2008: Abciximab in Patients with AMI Undergoing Primary PCI After Clopidogrel Pretreatment: BRAVE-3 Trial by Dr. Julinda Mehilli
Sunday, March 30, 2008: Vascular Protection in High-Risk Non-ST Elevation Acute Coronary Syndromes: Angioplasty Balloon-associated Coronary Debris and the EZ FilterWire by Dr. Mark Webster
Saturday, March 29, 2008: Comprehensive Meta-Analysis of DES vs. BMS Randomized Trials and Registries by Dr. Ajay J. Kirtane
Saturday, March 29, 2008: Bivalirudin Versus Unfractionated Heparin in Biomarker Negative Patients With Stable and Unstable Angina Undergoing PCI: ISAR-REACT 3 by Dr. Adnan Kastrati
Saturday, March 29, 2008: Eight Months Angiographic Follow-up in Patients Randomized to Crush or Culotte Stenting of Coronary Artery Bifurcation Lesions: The Nordic Bifurcation Stent Technique Study by Dr. Pål Gunnes
Saturday, March 29, 2008: Long-Term Clinical Outcome After First Definite Stent Thrombosis: Dutch Stent Thrombosis Registry by Dr. J.W. van Werkum
Saturday, March 29, 2008: Percutaneous Coronary Interventions in Facilities without On-Site Cardiac Surgery: A Report from the National Cardiovascular Data Registry (NCDR)
Saturday, March 29, 2008: Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis by Dr. Stephen D. Wiviott
Saturday, March 29, 2008: Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel low response: A Multicentre Randomized Prospective Study by Dr. Laurent Bonello
Friday, March 28, 2008: Comprehensive Meta-Analysis of DES vs. BMS Randomized Trials and Registries by Ajay J. Kirtane, M.D., S.M. and Gregg W. Stone, M.D.
Monday, March 17, 2008: Statistics for the Interventionalist by Dr. Gregory J. Dehmer
Tuesday, March 11, 2008: The Total Artificial Heart:An Evolving Role in the Management of End-Stage Heart Failure by Dr. Marvin J. Slepian
Monday, March 3, 2008: In-stent Restenosis and Late Stent Thrombosis by Dr. Roxana Mehran
Wednesday, February 27, 2008: Contrast Induced Nephropathy: Predictors, Prevention, and Management by Dr. Roxana Mehran
Friday, February 22, 2008: Hemodynamics for the Interventional Cardiologist by Dr. Gregory Dehmer
Thursday, February 14, 2008: Update on Novel Antiplatelet Agents Under Advanced Clinical Development by Dominick J. Angiolillo, MD, PhD, FACC, FESC
Thursday, February 14, 2008:
A
Randomized Study Assessing the Impact of Cilostazol on Platelet Function
Profiles in Patients with Diabetes Mellitus and Coronary Artery Disease
on Dual Antiplatelet Therapy: Results of the OPTIMUS-2 (Optimizing
anti-Platelet Therapy In diabetes MellitUS) Study by Dominick J.
Angiolillo, MD, PhD
Thursday, February 14, 2008:
Antiplatelet Resistance: What Does it Mean
and What Should/Can we do About it? by Dominick J. Angiolillo, MD,
PhD, FACC, FESC
 Friday,
December 21, 2007:
False Positive ST Elevation in Patients
Undergoing Direct Percutaneous Coronary Intervention
by David M. Larson |
Friday, December 7, 2007: PRasugrel IN Comparison to Clopidogrel for Inhibition of PLatelet Activation and AggrEgation Results from the PRINCIPLE - TIMI 44 Study
 Wednesday, November 14, 2007: Regional STEMI Networks in Southern California Reduce Door-to-Balloon Times: Pooled Data from 4 Counties Results from the Southern California STEMI Consortium by Ivan Rokos
|
Friday, November 9, 2007: Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts by Laura Mauri
Wednesday, November 7, 2007: Impact of Thromboaspiration during Primary PCI on Microvascular Damage and Infarct Size: Acute and Long term CE-MRI Evaluation Results from the EXPIRA Trial by Gennaro Sardella
Wednesday, November 7, 2007: A Randomized Trial of Genotype-uided versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation Results from the Couma-Gen Study by Jeffrey L. Anderson
Tuesday, November 6, 2007: The Resynchronization Therapy in Normal QRS (RethinQ) Study by John F. Beshai
Monday, November 5, 2007: Bivalirudin With and Without Eptifibatide for Elective Stenting: A Pharmacodynamic Study of Platelet Reactivity in Relation to the Occurrence of Periprocedural Myocardial Infarction Results from the CLEAR PLATELETS-2 Study
Monday, November 5, 2007: Results of the RACE Project
BREAKING NEWS Sunday, November 4: Results of the TRITON- TIMI 38 Trial
Results of the BRIEF-PCI Trial by Anthony Fung
Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Safety Results from the Endeavor by Laura Mauri
Results of the ARMYDA-5 Trial by Germano Di Sciascio
Results of the ARMYDA-4 Trial by Germano Di Sciascio
Evidence-Based Medicine Therapies in ACS: From Principles to Practice by Magnus Ohman
A Prospective, Randomized Trial of a Paclitaxel-Eluting Balloon in In-Stent Restenosis 2-Year Results from PACCOCATH ISR 1 and 2 by Bruno Scheller
TRA-PCI update on the new antiplatelet agents: PAR-1 inhibitors by David Moliterno
Clopidogrel Response Variability and Resistance by Paul Gurbel
Eric Peterson provides an update on the CRUSADE and ACTION Registries
Benefits of aggressive lipid lowering before and after PCI and reperfusion by M. Gibson
Prolonged Infusion of Clevidipine Results in Safe and Predictable Blood Pressure Control in Patients with Acute Severe Hypertension Results from the VELOCITY Trial
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction 30 Day Results of the HORIZONS AMI Trial
Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty Results of the ARMYDA-5 Study
Impact of thrombectomy with EXPort catheter in Infarct Related Artery on procedural and clinical outcome in patients with AMI The EXPIRA Trial
Thromboaspiration in Acute ST-Elevation MI Improves Myocardial Reperfusion EXPORT STUDY-First Report
A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease 1-Year Follow-Up and Subgroup Analysis for the SPIRIT III trial
Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis ISAR-TEST 3 Randomized Trial
A Randomized Comparison of a Zotarolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease The ENDEAVOR 4 Trial
The European Randomized CoStar Trial: Cobalt-Chromium Paclitaxel-eluting Stent vs. identical BMS Results of the EuroSTAR II Trial
A prospective randomized controlled study of the Medtronic Interceptor® PLUS Coronary Filter System for PCI of Degenerative SVG Results of the AMEthyst Trial
Effect of Distal Embolization on Myocardial Perfusion Reserve Following Percutaneous Coronary Intervention: A Quantitative MR Perfusion Study. Joseph Selvanayagam, M.D.
Patients with ACS undergoing PCI after randomization to Heparin plus GP IIb/IIIa Inhibitors Vs. Bivalirudin with or whitout GP IIb/IIIa Inhibitors. The results of the ACUITY PCI Trial. Harvey White, M.D.
Safety and Efficacy of Bivalirudin in Patients with Non-ST
Elevation ACS undergoing Medical Management.
One Year Results from the ACUITY Trial. Walter Desmet, M.D.
Cardiac Magnetic Resonance in patients with acute MI.
Michael Shapiro, M.D., et al
Long term Follow-up of the Diabetes
I (DIABETes and Sirolimus Eluting Stent) Trial.
Manel Sabate, M.D. et al.
Drug Eluting Stents Vs. Bare Metal Stents in Sweden.
The Results of the SCAAR Trial. Stefan James M.D. et al.
Abciximab Vs. Placebo in Patients with NSTEMI undergoing PCI
Aftrer Pretreatment with Clopidogrel. The ISAR-REACT 2
Trial. The ISAR-REACT 2 Trial. M. Seyfarth
M.D. et al
Sirolimus Eluting Stents Vs. Bare Metal Stents Implantation
Assisted by Systematic GP IIb/IIIa Infusion in Patients with MI.
The STRATEGY Trial. Marco Valgimigli M.D.et al
Safety and efficacy of Intravenous Enoxaparin in Eective
Percutaneous Coronary Intervention: An International Randomized
Evalutaion. The STEEPLE Trial. G. Montalescot
M.D. et al.
Efficacy Non-Invasive Ventilation in
Patients with Acute Cardiogenic Pulmonary Edema.
The 3 CPO Trial . David Newby M.D. et al.
Action in Diabetes and Vascular Disease . The ADVANCE Trial.
S. MacMahon et al.
Substudy of Michelangelo: OASIS 5- Women's
Substudy. Eva Swahn M.D.
5-year
Outcome of the German Epidemiological
Trial on Ankle Brachial Index.
The getABI Study. Curt
Diehm, M.D.
Predictor of Response of CRT. The results of the PROSPECT
Study. Cecilia Linde, M.D.
Western Norway B-vitamin Intervention Trial.
The WENBIT Trial. Marta Ebbing, M.D.
A
Regionalized Approach to Patients with AMI . The Mayo Clinic
Experience.
Prognostic Value of B-Type
The FAST Trial .
The EMERALD Trial - D
Red Cell distribution Width as a Novel Prognostic Marker
in Heart Failure: Data from the CHARM Program and the DUKE
Databank.
Michael Felker, M.D.
The MULTI-STRATEGY Trial. Evaluation of single high-bolus dose
tirofiban Vs. abciximab and SES Vs. BMS in acute MI.
Marco Valgimigli, M.D.
The
GRACE Registry. Combining warfarin after coronary stenting.
Michael Nguyen, M.D.
Natural History of Lone Atrial Fibrillation. 30-year Follow-up
Study.
Paul A. Friedman, M.D.
Infarct Transmurality Size Assessed by Delayed Enhancement MRI:
Time-to-Treatment, ST-Segment Resolution, and TIMI-Flow Grades.
Holger Thiele, M.D.
Impact of Platelet Reactivity Following Clopidogrel
Administration on Drug Eluting Stent Thrombosis. David
Antoniucci, M.D.
|
Slide Library / Menu with Thousands of Slides Click Here |
|
New Each Week! |
Powerpoint
Case StudiesInterpreting COURAGE: One Interventional Cardiologist’s Perspective Duane S. Pinto, M.D.
The PROGRESS-AMS Study. Clinical performance and angiographic results of coronary stenting with Absorbable Metal Stents. Raimund Erbel, MD.
DEFER STUDY: 5-YEAR FOLLOW-UP
A Multicenter Randomized Study to Compare
Deferral Versus Performance of PCI of
Non-Ischemia-Producing Stenoses. Nico H.J.
Pijls, MD, PhD
PCI in Patients Receiving Enoxaparin or UFH Following
Fibrinolytic Therapy for STEMI:PCI ExTRACT-TIMI 25.
C. Michael Gibson, MD
CHARISMA: The CAPRIE-like Cohort. Deepak Bhatt, MD.
Three Year Result of Intracoronary Stand-alone
Bolus Administration of Eptifibatide During
Coronary Intervention Walid
M. Hassan, MD. Hassan et al. Catheterization and
Cardiovascular Interventions. 2007; 69 (6): S93.
Superiority of 600 mg of Clopidogrel as a Loading Dose: A
MetaAnalysis
Presented at SCAI 07. Biondi-Zoccai and Abbate et al
Clopidogrel Use and Death/MI After Stent Implantation in a
Diabetic Population. Results from the SUNSET Registry.
Somjot Brar MD, et al.
Review and Update for Practitioners: ACS, PCI and CABG in Women.
Jeffrey J. Popma, MD.
Randomized Trial of Sirolimus Stent Vs Bare Metal Stent in Acute
Myocardial Infarction. SESAMI Trial. Mauricio Menichelli,
MD, et al.
Intracoronary Streptokinase After Primary Percutaneous Coronary
Intervention. Murat Sezer, MD, et al.
Impact of DES on Revascularization Choices in Patients with
Acute Coronary Syndromes and Multivessel Coronary Disease:
Results from The CRUSADE Quality Improvement Initiative.
Gogo Prospero M.D., et al.
White Blood Cell Count Secular trend and Mortality: The
Baltimore Longitudinal Study of Aging.
Carmelinda dr.ssa Ruggiero M.D., et al.
Recent Slides
COURAGE Resource Center
COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive Guideline-Driven Drug Evaluation. Bill Boden, M.D.
COURAGE Design and Baseline Characteristics of the COURAGE trial by Bill Boden
Dr. Bill Boden discusses the results of the COURAGE trial on C TV
AVERT Atorvastatin Versus Revascularization Treatments
PCI vs Conservative Therapy for Chronic CAD Results from Meta-Analysis 2005
Survival PCI vs Medical Management The answer may depend on patient risk
Risk Factor Profiling by Cardiac MRI: Can it be a reality?
Katherine C. Wu, MD.
Long-Term Prognosis Associated with Coronary Calcification
Matthew J. Budoff, MD.
ADHERE: Admission B-Type Natriuretic Peptide Levels and
In-Hospital Mortality in Acute Decompensated Heart Failure
Gregg C. Fonarow MD.
The
CRUSADE National Quality Improvement Initiative:
Characteristics, Management, and Outcomes of 5,557
Patients Age ≥90 Years With Acute Coronary Syndromes. Adam H.
Skolnick, MD.
Evaluation by Optical Coherence Tomography (OCT) of Neointimal
Coverage of Sirolimus-Eluting Stent Three Months After
Implantation Masamichi Takano, MD. et al
Analysis of 36 Reported Cases of Late Thrombosis in Drug-Eluting
Stents Placed in Coronary Arteries. Ramin
Artang, MD and Robert S. Dieter, MD. et al
Randomized Early versus Late AbciXimab in Acute Myocardial
Infarction treated with primary coronary intervention (RELAx-AMI
Trial)
Mauro Maioli, M.D.
Clinical Implications of Clopidogrel non-responsiveness.
Dominick Angiolillo, MD, PhD
Post-Conditioning the Human Heart to Reduce Infarct Size. Michel Ovize, MD, PhD.
ACUITY 1 Year Results A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the ACUITY Trial. Gregg W. Stone, MD
Randomized Double Blind Trial of Thrombin Receptor Antagonist (TRA) Moliterno et al
ARMYDA-ACS: Atorvastatin Pretreatment
Improves Outcome in Patients With Acute Coronary Syndromes
Undergoing Percutaneous Coronary Intervention
TRIUMPH The Tilarginine Acetate Injection in a Randomized International Study in Unstable Acute Myocardial Infarction Patients with Cardiogenic Shock Trial. Judith S. Hochman, M.D.
ARISE Aggressive Reduction of Inflammation Stops Events. Presented by Dr. Jean-Claude Tardif
Aliskiren and Valsartan for Antihypertensive Therapy. Presented by Dr. Suzanne Oparil
ECLIPSE Blood Pressure Control with Clevidipine Compared with Nitroglycerin, Sodium Nitroprusside, or Nicardipine in the Treatment of Peri-operative Hypertension Solomon Aronson, M.D.
ECLIPSE BP Control Blood Pressure Control is an Independent Predictor of Short-term Mortality in Cardiac Surgery Patients. Solomon Aronson, M.D.
RACE: Reperfusion in AMI in Carolina Emergency Departments. Christopher Granger, MD.
OASIS 6: Efficacy and safety of fondaparinux in elderly patients with STEMI. Ron J.G. Peters, MD.
Implications of Preoperative Thienopyridine Use Prior to Coronary Bypass Graft Surgery in Patients with ACS: A Report from the ACUITY Trial. Ramin Ebrahimi, MD.
ANTHEM-TIMI 32: Results of the Dose- Ranging and Heparin De-Escalation Phases of the ANTHEM-TIMI 32 Trial. Robert P. Giugliano, MD, SM.
ABSORB First-ever human trial of a fully bioabsorbable everolimus-eluting stent. Presented by Dr. Patrick W. Serruys
DEDICATION Distal protection using a Filterwire compared with conventional intervention among patients with STEMI undergoing PCI. Presented by Dr. Leif Thuesen.
ERASE Effect of rHDL on Atherosclerosis-Safety and Efficacy. Presented by Dr. Jean-Claude Tardif.
ILLUSTRATE Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation. Presented by Dr. Steven E. Nissen.
METEOR Measuring Effects of Intima-Media Thickness: An Evaluation of Rosuvastatin. Presented by Dr. John R. Crouse III. View an animated presentation. View other resources
NAPA Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery. Mark J. Russo, MD, MS.
SPIRIT III
Clinical, Angiographic, and IVUS Results from the Pivotal
U.S. Randomized SPIRIT III Trial of the XIENCE V
Everolimus-eluting Coronary Stent System. Gregg W. Stone,
MD.
FUSION II Follow-Up Serial Infusions of Nesiritide for the Management of Patients With Heart Failure.
EVEREST
Efficacy of Vasopressin antagonism in hEart failuRE: outcome
Study with Tolvaptan (EVEREST). Marvin A. Konstam, MD
10 Lessons Learned from CRUSADE: Can Rapid Risk
Stratification of Unstable Angina Patients Suppress Adverse
Outcomes with Early Implementation of the ACC and AHA
Guidelines? Eric D. Peterson, MD, FACC.
Toxicity and Screening Recommendations for Amiodarone Use. Peter Zimetbaum, MD, FACC.
Friday,
April 4, 2008: 
